Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer
Science Advances · 05.12.2025 · 11 (49)
DOI: 10.1126/sciadv.ady7032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 05.12.2025. Verfasst von Daesun Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health Grant, National Research Foundation of Korea (NRF) grants.
Abstract (Originalsprache)
Acquired drug resistance mutations in epidermal growth factor receptor (EGFR) present a substantial clinical challenge in treating non–small cell lung cancer (NSCLC). While EGFR oligomerization plays a pivotal role in modulating receptor signaling, its relationship with resistance mutations remains unclear. Here, we investigated the real-time link between oligomerization of oncogenic and resistant EGFR mutants and downstream signaling using a fluorescent protein–based proximity probe and signaling reporter in living cells. We found that EGFR mutants resistant to tyrosine kinase inhibitors (TKIs) exhibited higher oligomerization than did wild-type EGFR with or without EGF. The efficacy of TKIs and allosteric drugs inversely correlated with receptor oligomerization. Furthermore, sterically disrupting EGFR oligomerization by genetically fusing a bulky protein to resistant mutants overcame resistance and suppressed proliferation. Moreover, extracellular application of bulky EGFR binders suppressed resistant mutants by disrupting oligomerization. These findings highlight steric disruption of EGFR oligomerization as a promising strategy for overcoming therapy resistance in NSCLC and introduce a versatile screening platform for developing competitive and allosteric inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Stanford University, Stanford, CA 94305, USA.
- Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
- College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA.
- Department of Chemistry, KAIST, Daejeon 34141, Republic of Korea.
ORCID-Profile: Daesun Song, Michael Z Lin, Yongwon Jung
Förderung
- NIGMS NIH HHS
- National Institutes of Health Grant
- National Research Foundation of Korea (NRF) grants
- Ministry of Science and ICT, South Korea grant
- Human Frontier Science Program Long Term Postdoctoral Fellowship
- Global Science Research Center Program
- Stanford Bio-X Interdisciplinary Initiatives Seed Grant
Zitieren
APA
Song, D., Jang, J., Lin, M. Z., & Jung, Y. (2025). Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer. Science Advances, 11(49). https://doi.org/10.1126/sciadv.ady7032
Vancouver
Song D, Jang J, Lin MZ, Jung Y. Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer. Science Advances. 2025;11(49). doi:10.1126/sciadv.ady7032
BibTeX
@article{Song2025,
author = {Song, Daesun and Jang, Jaebong and Lin, Michael Z and Jung, Yongwon},
title = {Steric disruption of EGFR oligomerization overcomes therapy resistance in non–small cell lung cancer},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {49},
doi = {10.1126/sciadv.ady7032}
}
EUVIMED